Perez-Martinez Antonio, Lastra Rodrigo Anarbella, Ramos Boluda Esther, Gonzalez Martinez Berta, Alcolea Sánchez Alida, Hernandez Oliveros Francisco
Pediatric Hemato-Oncology Department, La Paz University Hospital, Universidad Autónoma de Madrid, Paseo de la Castellana 261, 28046, Madrid, Spain.
CIBERER-ISCIII, IdiPAZ-CNIO Pediatric Onco-Hematology Clinical Research Unit, Madrid, Spain.
Adv Ther. 2025 Jul;42(7):3011-3019. doi: 10.1007/s12325-025-03246-z. Epub 2025 May 30.
This article is coauthored by the parents of a young patient and the medical team who cared for her.Together, they recount their shared experience with tabelecleucel, a novel therapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV + PTLD). The patient's parents offer a deeply personal perspective, reflecting on several years of struggle marked by unwavering hope and trust in the medical professionals who have supported their daughter throughout her journey. The pediatric hemato-oncologist who advocated for the use of tabelecleucel described the case as unique worldwide.Their joint testimony tells the remarkable story of how tabelecleucel, despite an initially unclear biological rationale, achieved a reversal of a severe case of EBV + PTLD that had progressed to a point considered beyond recovery and associated with a dire prognosis.
本文由一位年轻患者的父母与照顾她的医疗团队共同撰写。他们一起讲述了他们使用tabelecleucel的共同经历，这是一种治疗爱泼斯坦-巴尔病毒相关移植后淋巴细胞增生性疾病（EBV + PTLD）的新型疗法。患者的父母提供了一个非常个人化的视角，反思了数年的艰难历程，其间始终怀着坚定的希望，并信任在女儿整个治疗过程中给予支持的医疗专业人员。主张使用tabelecleucel的儿科血液肿瘤学家称该病例在全球范围内都很独特。他们的联合证词讲述了一个非凡的故事：尽管tabelecleucel最初的生物学原理尚不清楚，但它却使一例严重的EBV + PTLD得到了逆转，该病例已发展到被认为无法恢复且预后极差的程度。
